Abstract
Although an expanding array of effective treatments has resulted in recent improvement in survival of patients with mantle cell lymphoma (MCL), outcomes remain heterogeneous, and identification of prognostic factors remains a priority. We assessed the prognostic impact of time to progression of disease (POD) afterfirst-line therapy among455 patients with relapsed MCL. Patients were categorized by duration of first remission as PRF/POD6, defined as progressive diseaseduringinduction orPODwithin6monthsof diagnosis (n565;14%);POD6-24, definedasPODbetween 6and24months after diagnosis (n5153; 34%);andPOD.24, defined asPOD.24monthsafterdiagnosis(n5237;53%).ThemedianoverallsurvivalfromPOD(OS2) was 1.3 years (95%confidence interval [CI], 0.9-2.4) for patients with PRF/POD6, 3 years (95% CI, 2-6.8) for those with POD6-24, and 8 years (95%CI, 6.2-NR) for those withPOD.24. Median OS2 was inferior in patients with early POD (defined as PRF/POD6 or POD6-24) after both intensive and less intensive frontline treatment. The prognostic performance of time until PODwasreplicated inanindependent cohort of 245 patients with relapsedMCL,withmedian OS2 of 0.3 years (95%CI, 0.1-0.5) for PRF/POD6, 0.8 years (95%CI, 0.6-0.9) for POD6-24, and 2.4 years (95%CI 2.1-2.7) for POD.24. Early POD is associated with inferior OS2 in patients with relapsed MCL, identifying a high-risk population for future prospective studies.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 5179-5189 |
| Number of pages | 11 |
| Journal | Blood Advances |
| Volume | 5 |
| DOIs | |
| State | Published - Dec 14 2021 |
Funding
Conflict-of-interest disclosure: D.V. has received research funding from Roche and AstraZeneca and has consulted for Roche, Celgene, AbbVie, Seagen, Kite/Gilead, Lundbeck, Nanostring, AstraZeneca, Pur-due Pharma, Sandoz, and Janssen. K.M. has received research funding from Bristol-Myers Squibb, Novartis, and Pharmacyclics and has consulted for ADC Therapeutics, AstraZeneca, Beigene, Bristol-Myers Squibb, Celgene, Kite, Morphosys, and Seattle Genetics. A.S.G has received research funding from Roche Canada, Janssen, AbbVie, and AstraZeneca; has served on advisory boards for Janssen, AbbVie, Astra-Zeneca, and Sandoz; and has received honoraria from Janssen. V.B. has served on the advisory board for Gamida Cell Kite and has received research funding from Karyopharm, FATE, Bristol Myers Squibb, and Incyte. J.N.G. has received research support from Loxo and has consulted for Genetech, AbbVie, and TG Therapeutics. S.K.B. has served on advisory boards for Seagen, Daiichi Sanko, and Atara and has consulted for Acrotech and Seagen. A.V.D. has received research funding from Aptose Biosciences, AstraZeneca, Gilead Sciences, Takeda Oncology, Genentech, Bayer Oncology, Verastem Oncology, and Bristol-Myers Squibb and has consulted for AstraZeneca, Abbvie, Bei-gene, Bayer Oncology, Bristol-Meyers-Squibb, Genentech, Karyo-pharm, Pharmacyclics, TG Therapeutics, Nurix, and Rigel Pharmaceuticals. N.S.G. has received research funding from Genetech and has consulted for Kite and Tessa Therapeutics. R.K. has received research funding from Kite/Gilead Sciences, Juno/Bristol-Meyers-Squibb, and Takeda Oncology and has served on advisory boards for Kite/Gilead Sciences, Juno/Bristol-Meyers-Squibb, Janssen, and Karyo-pharm and on the speakers bureau for AstraZeneca, Kite/Gilead Sciences, and BeiGene. B.T.H. has received research funding from and has consulted for Genentech. P.M. has consulted for ADC Therapeutics, AstraZeneca, Bayer, Bristol Myers Squibb, Cellectar, Epizyme, Gilead, Incyte, Janssen, Karyopharm, Merck, Regeneron, Takeda, Teneobio, and Verastem; has received research funding from Celgene/Bristol Myers Squibb, Takeda, and Gilead/Kite; has consulted for Celgene/ Bristol Myers Squibb, Karyopharm, and Gilead/Kite; and has served on the speaker’s bureau for Celgene/Bristol Myers Squibb, BeiGene, AstraZeneca, and Gilead/Kite. N.E. has served on the speaker’s bureau for Verastem and Beigene and has consulted for Karyopharm and Gen-zyme. M.H. has received research funding from Takeda, Spectrum Pharmaceuticals, and Astellas Pharma; has consulted for Janssen, Incyte, ADC Therapeutics, Celgene, Omeros, Verastem, and MorphoSys; and has served on the speaker’s bureau for Sanofi Genzyme, AstraZe-neca, and BeiGene. T.S.F. has received research funding from Novartis, TG Therapeutics, Portola, and Curis; has consulted for Beigene, Gen-entech, Adaptive Biotechnologies, AbbVie, Verastem, Kite, MorphoSys, AstraZeneca, Pharmacyclics, and Sanofi; and has served on speaker boards for Genentech, Sanofi, Seattle Genetics, AstraZeneca, Cel-gene/Bristol-Myers Squibb, and Adaptive Biotechnologies. C.R.F. has received research funding from Kite, Gilead, Celgene, AbbVie, Acerta, Karyopharm, Takeda, Roche, and TG Therapeutics and has consulted for Janssen/Pharmacyclics, Spectrum, Gilead/Kite, Celgene, AbbVie, Karyopharm, Bayer, Denovo Biopharma, Takeda, BeiGene, and Genen-tech. J.B.C. has received research funding from Janssen, Adicet, Astra-Zeneca, Genentech, Cellectar, and Kite/Gilead and has consulted for Genentech, Bristol Myers Squibb, Novartis, LAM, BioInvent, AstraZe-neca, Seagen, and Loxo. The remaining authors declare no competing financial interests. This work was supported in part by the Biostatistics and Bioinfor-matics Shared Resource of Winship Cancer Institute of Emory University and the National Institutes of Health, National Cancer Institute (NIH/NCI; P30CA138292) and by the Center for Clinical and Translational Science Bioinformatics Shared Resource of The Ohio State University (UL1TR002733). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
ASJC Scopus subject areas
- Hematology
